Abstract
The use of the nanotechnology in the development of new drugs has had in the last years a very widespread presence in the pharmaceutical industry. Diverse diseases that are treated by means of conventional administration systems as capsules, covered tablets or injectable not always have the therapeutic effect expected due to its bioavailability, solubility in aqueous medium and the stability of the excipients that they accompany to the drug. It is for this reason that the formation of nanoparticles either from organic sources as natural polymers like chitosan or synthetic like poly-ε-caprolactone (PCL) affording the inclusion of diverse liposoluble active compounds, they have given excellent results in the incipient treatment of behavior disorders that are necessary drugs that should remain close of active sites at the time. Thus, this review shows the formation of nanoparticles for a direct application of the psychiatric medication, may be considered as a new pharmacological tool by its low cytotoxicity and high efficiency.
Keywords: Mental disorders, Nanoparticles, Nanotechnology, Neurodegenerative diseases.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication
Volume: 15 Issue: 4
Author(s): Eduardo Sobarzo-Sánchez, Seyed Mohammad Nabavi, Eugenio Uriarte and Lourdes Santana
Affiliation:
Keywords: Mental disorders, Nanoparticles, Nanotechnology, Neurodegenerative diseases.
Abstract: The use of the nanotechnology in the development of new drugs has had in the last years a very widespread presence in the pharmaceutical industry. Diverse diseases that are treated by means of conventional administration systems as capsules, covered tablets or injectable not always have the therapeutic effect expected due to its bioavailability, solubility in aqueous medium and the stability of the excipients that they accompany to the drug. It is for this reason that the formation of nanoparticles either from organic sources as natural polymers like chitosan or synthetic like poly-ε-caprolactone (PCL) affording the inclusion of diverse liposoluble active compounds, they have given excellent results in the incipient treatment of behavior disorders that are necessary drugs that should remain close of active sites at the time. Thus, this review shows the formation of nanoparticles for a direct application of the psychiatric medication, may be considered as a new pharmacological tool by its low cytotoxicity and high efficiency.
Export Options
About this article
Cite this article as:
Sobarzo-Sánchez Eduardo, Nabavi Mohammad Seyed, Uriarte Eugenio and Santana Lourdes, Nanoparticles in the Treatment of Mental Disorders: A New Tool in the Psychiatric Medication, Current Topics in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1568026615666150108124533
DOI https://dx.doi.org/10.2174/1568026615666150108124533 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Reflection on Existence of Neural and Non-Neural Pathway for Nose- to- Brain Using a Novel Formulation of an Anticholinesterase Piperidine Derivative
Current Nanoscience Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Intranasal Drug Delivery for Brain Targeting
Current Drug Delivery Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Prepontine Chordoma Presenting with MRI Features of an Epidermoid Cyst: Case Presentation and a Mini-Review
Current Medical Imaging RNA Interference and Amyotrophic Lateral Sclerosis
Current Drug Metabolism Imaging and Clinical Features of Neurocutaneous Melanosis in the Pediatric Population
Current Medical Imaging Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening The Pathogenesis of Neurotrauma Indicates Targets for Neuroprotective Therapies
Current Neuropharmacology Executive Function Impairments in Patients with Depression
CNS & Neurological Disorders - Drug Targets